entacingene turiparvovec (AAV-CNGB3)
/ MeiraGTx
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
June 11, 2025
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
(clinicaltrials.gov)
- P=N/A | N=34 | Terminated | Sponsor: MeiraGTx UK II Ltd | Completed ➔ Terminated; Strategic decision to not further develop AAV8-hCARp.hCNGB3 and AAV8-hG1.7p.coCNGA3. The decision is not due to safety concerns.
Trial termination • Achromatopsia • Gene Therapies • Ophthalmology
May 03, 2024
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
(clinicaltrials.gov)
- P1/2 | N=34 | Completed | Sponsor: MeiraGTx UK II Ltd | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Apr 2024 | Trial primary completion date: Jan 2026 ➔ Apr 2024
Gene therapy • Trial completion • Trial completion date • Trial primary completion date • Achromatopsia • Gene Therapies • Ophthalmology
January 14, 2022
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
(clinicaltrials.gov)
- P1/2; N=34; Active, not recruiting; Sponsor: MeiraGTx UK II Ltd; Recruiting ➔ Active, not recruiting; N=72 ➔ 34; Trial completion date: Aug 2024 ➔ Jan 2026; Trial primary completion date: Jul 2024 ➔ Jan 2026
Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Achromatopsia • Gene Therapies • Ophthalmology
March 14, 2021
[VIRTUAL] A002 GENES, ENVIRONMENT, AND TREATMENT: CHARACTERIZING RISK IN ILD
(ATS 2021)
- No abstract available
May 16, 2021
"#ATS2021 Mini Symposium A002 Gene, Environment, And Treatment: Characterizing Risk in ILD 5/16/2021 8:00:00 AM - 5/16/2021 9:30:00 AM EDT"
(@ATS_EOPH)
July 08, 2020
Gene Therapy for Achromatopsia (CNGB3)
(clinicaltrials.gov)
- P1/2; N=23; Completed; Sponsor: MeiraGTx UK II Ltd; Trial primary completion date: May 2019 ➔ Oct 2019
Clinical • Trial primary completion date • Achromatopsia • Ophthalmology
February 05, 2020
Gene Therapy for Achromatopsia (CNGB3)
(clinicaltrials.gov)
- P1/2; N=23; Completed; Sponsor: MeiraGTx UK II Ltd; Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 7
Of
7
Go to page
1